華為殺進 AI 研發藥物領域，擴大與中國藥廠合作
TechNews (TW)zh-TW
中國科技巨頭華為加速布局 AI 藥物研發，計劃與中國製藥企業合作，從已有藥物研發與研究，延伸至臨床應用與實踐。 […]
This is a short summary published by AI Global Wire. The full article is owned and hosted by TechNews (TW) — open it there to read it in full.
Read the full story at TechNews (TW)Related AI news
- French chip materials maker Soitec locks customers into multi-year deals as AI wafer demand surgesEconomic Times Tech · August 31, 2026
- MetaX posts first-half profit while China's AI GPU rivals splitDIGITIMES · August 31, 2026
- IPO documents: SoftBank's SB Energy plans to file for an IPO as soon as this week, aiming to raise $5B to $7B, and has awarded OpenAI warrants worth ~$5.5B (Anissa Gardizy/Wall Street Journal)Techmeme · August 31, 2026
- OpenAI、Anthropic 狂搶，數萬台 Mac mini、Mac Studio 成 AI 新寵TechNews (TW) · August 31, 2026
- OpenAI issued warrants worth $5.5 billion in SB Energy, WSJ reportsEconomic Times Tech · August 31, 2026
- 7 月製造業景氣睽違 5 年亮紅燈，下半年續航力待觀察TechNews (TW) · August 31, 2026